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Abstract
Gerstmann-Stra ¨ussler-Scheinker (GSS) disease is a dominantly inherited prion disease associated with point mutations in the
Prion Protein gene. The most frequent mutation associated with GSS involves a proline-to-leucine substitution at residue
102 of the prion protein, and is characterized by marked variability at clinical, pathological and molecular levels. Previous
investigations of GSS P102L have shown that disease-associated pathological prion protein, or PrP
Sc, consists of two main
conformers, which under exogenous proteolysis generates a core fragment of 21 kDa and an internal fragment of 8 kDa.
Both conformers are detected in subjects with spongiform degeneration, whereas only the 8 kDa fragment is recovered in
cases lacking spongiosis. Several studies have reported an exclusive derivation of protease-resistant PrP
Sc isoforms from the
mutated allele; however, more recently, the propagation of protease-resistant wild-type PrP
Sc has been described. Here we
analyze the molecular and pathological phenotype of six GSS P102L cases characterized by the presence of 21 and 8 kDa
PrP fragments and two subjects with only the 8 kDa PrP fragment. Using sensitive protein separation techniques and
Western blots with antibodies differentially recognizing wild-type and mutant PrP we observed a range of PrP
Sc allelic
conformers, either resistant or sensitive to protease treatment in all investigated subjects. Additionally, tissue deposition of
protease-sensitive wild-type PrP
Sc molecules was seen by conventional PrP immunohistochemistry and paraffin-embedded
tissue blot. Our findings enlarge the spectrum of conformational allelic PrP
Sc quasispecies propagating in GSS P102L thus
providing a molecular support to the spectrum of disease phenotypes, and, in addition, impact the diagnostic role of PrP
immunohistochemistry in prion diseases.
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Introduction
Prion diseases are fatal neurodegenerative disorders of humans
and animals, occurring as idiopathic, genetic, and iatrogenic
conditions [1]. Human prion disorders include Creutzfeldt-Jakob
disease (CJD), variant Creutzfeldt-Jakob disease, kuru, fatal
familial insomnia, sporadic fatal insomnia, and Gerstmann-
Stra ¨ussler-Scheinker (GSS) disease [2]. In these disorders, the
cellular prion protein, or PrP
C, is converted to a protease-resistant
conformer with abnormal sedimentation properties, or PrP
Sc [3].
In some prion diseases variant PrP
Sc discloses distinct proteolytic
sites generating a core fragment named PrP27-30 [4], reflecting
the tertiary structure of PrP
Sc, in addition to variable C-terminal
truncated fragments (CTFs) and internal fragments [5,6,7,8,9].
PrP
Sc conformers are classified on the basis of the glycosylation
status and the molecular mass of their protease-resistant
unglycosylated backbone, or PrP27-30 core fragment, migrating
at 21 kDa in type 1 PrP
Sc and at 19 kDa in type 2 PrP
Sc [10],
although controversial results have been obtained by different
authors who have proposed the classification of PrP27–30 into
four types [11]. However, several prion strains, either in naturally
occurring disorders or in experimentally-induced conditions,
harbour protease-sensitive PrP
Sc (sPrP
Sc) quasispecies, in associa-
tion or not with protease-resistant PrP
Sc (rPrP
Sc) [12,13,14];
importantly, sPrP
Sc molecules cause neurological dysfunction
[15,16]. The neuropathological hallmarks of prion diseases are
prion protein (PrP) deposition, spongiosis, astrogliosis, and
neuronal death [17]; however, it is still unknown which molecular
forms of PrP
Sc are detected by immunohistochemistry (IHC).
GSS is an autosomal dominant prion disease associated with
point mutations in the Prion Protein gene (PRNP). The most frequent
mutation associated with GSS involves a proline-to-leucine
substitution within the unstructured N-terminal region of the
PrP at codon 102 (P102L), segregating with methionine at codon
129 on the mutant allele [18]. Other mutations have been
described either at the N-terminal or at the C-terminal PrP region.
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in age of onset, disease duration, and the ample number of clinical
variants. However, phenotypic heterogeneity is also observed both
within and between pedigrees with the same mutation, especially
in P102L GSS cases [19,20,21]. Accordingly, while in some P102L
patients progressive gait disturbances, truncal ataxia, lower limb
hyporeflexia and dysarthria are the presenting clinical features,
followed over years by dementia and pyramidal signs, in other
cases a rapid evolving dementia, indistinguishable from sporadic
CJD (sCJD), is observed. As yet, the molecular basis for such clinical
variability remains to be fully explained. Neuropathological
examination in GSS P102L discloses marked variation in the degree
and brain regional distribution of spongiform changes, which largely
correlates with the biochemical detection of proteinase K (PK)-
resistant PrP
Sc with a core fragment of 21 kDa [8,9,22].
As opposed to the variable topographical distribution of
spongiform degeneration, typical multi-centric plaques are widely
distributed throughout cerebral and cerebellar cortical and
subcortical regions, and appear to be constituted by an abnormal
PrP isoform that upon PK-digestion generates an internal 8 kDa
fragment (PrP8), overall spanning from residues 74–90 to 146–
153; this fragment is natively present in brain extract of GSS
P102L, although is enriched after PK treatment. Experimental
transmission of GSS P102L brain tissues with only PrP8 induces
PrP-amyloid deposition, but not spongiform encephalopathy [23].
Earlier studies have shown that abnormal PrP isoforms detected
in P102L mutation derive from mutated PrP (PrP
M) [8]. Recently,
this view has been challenged and proof has been obtained of wild-
type PrP (PrP
Wt) involvement in three GSS P102L cases with the
21 kDa fragment [24]. Additionally, evidence has been provided
that in transgenic (Tg) mice overexpressing the P101L mutation
[Tg,(prnp,P101L)], corresponding to GSS P102L mutation,
spontaneous formation of mutant sPrP
Sc molecules occurs in
brain tissues [15,16]. Moreover, in Tg,(PrP,P101L) expressing
high levels of mutant PrP, spontaneous prion disease is
accompanied by generation of sPrP
Sc [14]. Endogenous genera-
tion of sPrP
Sc was also observed in Tg196 mice expressing lower
levels of P101L mutated protein (about 2-fold higher than wild
type), following inoculation with a synthetic peptide bearing the
P101L mutation [25]. While the occurrence of rPrP
Sc and sPrP
Sc
has been extensively investigated in experimental models of GSS
P102L, no such studies have been systematically performed in the
human disorder. The present study was designed to investigate in
eight subjects with GSS P102L the extent of the contribution of
PrP
M and PrP
Wt in the generation of PrP
Sc conformers, including
sPrP
Sc and rPrP
Sc molecules. For this purpose, we selected brain
tissues from six cases with the 21 kDa and the 8 kDa fragments,
either methionine homozygous or heterozygous at codon 129 of
the PRNP, and two cases harbouring only PrP8, both methionine
homozygous. Frozen brain samples were investigated by conven-
tional biochemical techniques, in addition to sensitive protein
separation techniques and Western blot with antibodies differen-
tially recognizing the two allelic forms of PrP
C and PrP
Sc.I n
addition, fixed tissues from the foregoing subjects were investigated
by IHC and PET-blot to assess the extent of the contribution of
distinct allelic PrP molecules to tissue deposition under different
patterns. The results reported here demonstrate (i) a major
contribution of PrP
Wt to the generation of rPrP
Sc species; (ii) the
propagation of considerable amounts of mutated and wild-type
sPrP
Sc molecules; (iii) the extensive tissue deposition and high PET
blot signals of both allelic PrP
Sc species in all cases, including
subjects lacking PrP27-30. Our findings strongly support exper-
imental studies showing a major role of sPrP
Sc in causing
neurodegeneration in a genetic human prion disease.
Results
Immunoblot analyses of protease-resistant PrP
Sc in P102L
GSS
Demographic, genetic, and clinical data of all investigated
subjects are summarized in Table 1. Following treatment with PK
and immunoblot with 3F4, frontal cortex homogenates from six
GSS P102L subjects showed the presence of three major PrP27-30
bands migrating at 30, 25, and 20 kDa, and a single 8 kDa band;
two cases showed only trace amounts of the 8 kDa fragment in the
absence of PrP27-30 (Fig. 1A). The migration of the unglycosy-
lated PrP27-30 band was intermediate as compared to type 1 and
type 2 sCJD-associated PrP
Sc, whereas the glycosylation profile
showed a relative abundance of the diglycosylated form, similar to
fCJD E200K, but at variance with the ‘‘monoglycosylated
Table 1. Demographic, molecular, and clinical features of investigated P102L GSS cases.
CASE (code) Codon 129 Gender Age at onset
Disease
duration Clinical signs at onset Symptoms at evolution
1
(91-466)
M/V M 56 60 Ataxia, dysarthria, depression Dementia
2
(92-331)
M/M M 31 36 Ataxia, dysarthria Cognitive decline, ataxia, dysarthria,
abnormal eye movements
3
(96-422)
M/M M 65 60 Ataxia, dysphasia and dysarthria Dementia, agitation, sleep disturbance
4
(98-196)
M/M M 57 9 Ataxia, mild cognitive impairment Cerebellar signs and dementia
5
(98-197)
M/V M 31 11 Confusion Mental deterioration, apraxia, ataxia
6
(2004-59)
M/M F 41 5 Mild cognitive impairment, behavioral
changes, dysarthria, mild ataxia
Abnormal sleep, agitation, dysphasia
7
(2005-51)
M/V M 46 72 Weakness, gait ataxia Dementia
8
(2005-52)
M/M M 50 36 Cognitive decline Behavioral disturbances, dementia
doi:10.1371/journal.pone.0032382.t001
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Differences in the migration of PrP27-30 core fragment persisted
after glycans removal (Fig. 1B, lanes 5–8), therefore suggesting a
common proteolytic cleavage site of glycosylated and unglycosy-
lated PrP
Sc species. Cerebellar homogenates were available in four
P102L subjects and showed the presence of barely detectable
amounts of the 8 kDa fragment in three cases, and of PrP27-30 in
one.
Immunoblots probed with ICSM 35 antibody, which fails to
recognize human PrP
M, while detecting PrP
Wt [24], showed the
presence of PK-resistant PrP
Sc in brains from subjects with PrP27-
30 (Fig. 1C). In all cases, ICSM 35 failed to detect PrP8, thus
confirming the exclusive origin of this internal fragment from the
mutated allele. Differently from 3F4-positive PrP27-30, including
the total pool of mutated and wild type rPrP
Sc, ICSM 35-positive
PrP27-30 showed a relative abundance of the monoglycosylated
forms, and a core fragment migrating at ,20 kDa. Semiquanti-
tative densitometric analyses showed that wild-type PK-resistant
PrP
Sc accounted for 5–10% of the total 3F4-reactive PK-resistant
PrP
Sc. Within each case, immunoblots with ICSM 35 and 3F4
showed similar results in brain homogenates from at least three
different samples of the frontal cortex.
Two-dimensional analysis of protease-resistant PrP
Sc in
P102L brains
After 2-D separation and immunoblot with 3F4, PrP27-30
resolved as two sets of glycosylated charge isomers of 30 and
27 kDa, with pIs ranging from 4.0 to 8.0, and three unglycosylated
20 kDa spots, migrating between 8.1-6.8; in addition, three basic
spots were seen in the 8 kDa zone (Fig. 2A). After deglycosylation,
two additional 3F4-reactive 20 kDa spots, pIs of 6.5 and 6.1, were
seen (Fig. 2B), whereas ICSM 35 detected three major spots at 8.1,
7.7, 7.3, and a minor spot at 6.8 (Fig. 2C). Taken together, the
PrP
Sc core fragment in GSS P102L is composed as follows: (i)
PrP
M accounts for two major 6.5 and 6.8 spots, and minor 6.1,
7.3, 7.7, and 8.1 charge isomers; (ii) PrP
Wt contributes a major 7.7
spot, and two 7.3 and 8.1 charge isomers (Fig. 2I). Immunoblot
with 3E2 showed additional spots in the acidic zone of the gel, with
an orthogonal migration between 20 and 14 kDa (Fig. 2D); after
deglycosylation, the PrP27-30 core fragment resolved as six spots
with pIs ranging from 6.1 to 8.1 (Fig. 2E), whereas CTFs of 16–
17 kDa and 12–14 kDa were confined to a 4.5–6 range (Fig. 2E).
The heterogeneous composition of the core fragment in P102L
GSS was not dependent on the glycosylation pattern, since the
PrP
Sc core fragment in fCJD E200K, which is characterized by a
‘‘diglycosylated dominant’’ pattern, was composed by a single 6.8
spot (Fig. 2F). Collectively, these results show that divergent allelic
PrP
Sc conformers and glycotypes propagate in GSS P102L.
Immunoblots of the detergent-insoluble fraction probed with
3F4 (Fig. 2G) and 3E2 (Fig. 2H), revealed PrP
Sc species migrating
at 20–30 kDa and 8 kDa, in addition to CTFs of 16–17 and 12–
14 kDa, thus demonstrating the occurrence of endoproteolytic
products, matching those obtained after PK digestion. Graphic
representation of the allelic contribution of PrP
M and PrP
Wt to
PK-resistant PrP species is illustrated in the cartoon (Fig. 2I)
Sedimentation velocity in sucrose gradients of mutated
and wild-type PrP in P102L GSS
As expected, in control human brains, small aggregates of 3F4-
and ICSM 35-reactive PrP
C species were recovered only in the top
fractions. On the contrary, in the six GSS cases with PK-resistant
PrP
Sc, 3F4-reactive species were collected in all gradient fractions,
being more abundant in fractions 9 to 11; the latter fractions
contained also higher Mr PrP aggregates, and, in addition, fraction
11 contained aberrant PrP species of 8–16 kDa (Fig. 3A); fractions
stained with mAb ICSM 35 disclosed the presence of small PrP
aggregated mainly in the top fractions, in addition to variable
amounts of large assemblies in the fractions 9–11, and to barely
detectable PrP forms in the intermediate fractions (Fig. 3B). The
distribution and association of aberrant PrP molecules in the two
cases lacking PK-resistant PrP
Sc, namely cases # 3 and # 8,
provided divergent results, as to the partitioning of 3F4- and
ICSM-positive PrP molecules throughout the fractions. Indeed,
3F4-positive PrP molecules were detectable throughout all
fractions, being more abundant in fractions 1–3 and 10–11, in
Figure 1. Molecular characterization of mutant and wild-type
protease-resistant PrP
Sc in GSS P102L. (A) Western blot with the
3F4 antibody of proteinase K-resistant PrP
Sc in GSS P102L subjects
shows the presence of three bands migrating at 29, 25 and 20 kDa
(cases 1–2 and 4–7), in addition to variable amounts of an 8 kDa
fragment (cases 1–8). (B) Comparative analysis of PrP27-30, before
(lanes 1–4) and after (lanes 5–8) PNGase F treatment, among GSS P102L
(lanes 1 and 5), sCJD MV2 subtype (lanes 2 and 6), fCJD E200K (lanes 3
and 7), and sCJD MM1 subtype (lanes 4 and 8). The core fragment of
GSS P102L PrP
Sc migrates at 20 kDa, in a zone intermediate between
type 1 and type 2 PrP
Sc. (C) Immunoblot analysis of proteinase K-treated
GSS P102L brain samples probed with ICSM 35, recognizing wild-type
PrP27-30. Molecular mass is shown in kDa.
doi:10.1371/journal.pone.0032382.g001
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on the contrary, ICSM 35-positive PrP aggregates provided a
decreasing signal through fractions 1 to 5 and a weak positivity in
the bottom fraction (Fig. 3D). PK-treatment in the six cases with
PK-resistant PrP
Sc showed the presence of PrP27-30 in all
fractions, more abundantly in those reaching the bottom of
gradient; the last two fractions also contained high amount of the
8 kDa fragment (Fig. 3E). In these samples, ICSM 35-positive
PrP27-30 was seen in fractions 9–11 (Fig. 3F). In cases lacking
PrP27-30, PK-resistant PrP species of 8 kDa were decorated by
mAb 3F4 in the bottom fractions (Fig. 3G), whereas ICSM 35-
positive species were completely degraded by the protease
treatment (Fig. 3H).
Protease-sensitive PrP
Sc conformers
Using the ‘‘mild PK’’ protocol, or limited digestion with PK at
4uC, in the six cases with PK-resistant PrP
Sc we detected levels of
3F4-positive sPrP
Sc higher than amounts of rPrP
Sc obtained with
the classical ‘‘harsh-PK’’ protocol. The signal of the cold-PK
resistant isoforms, including a high Mr smear, was greatly
enhanced after PTA precipitation, and reduced to a core fragment
migrating in a 20–22 kDa zone, after PNGase treatment (Fig. 4A).
Immunoblot with ICSM 35 showed that also the wtPrP
contributed to the pool of sPrP
Sc, although at lower levels than
the mutated PrP isoform (Fig. 4B). Intriguingly, moderate to high
amounts of 3F4-positive sPrP
Sc species were recovered in the two
cases lacking the 21 kDa fragment (Fig. 4C), in addition to ICSM
35-positive high Mr sPrP
Sc species (Fig. 4D, arrow). In all
investigated subjects, sPrP
Sc species included the 8 kDa fragment,
which was detected by the 3F4 antibody, but not the ICSM 35
(Table 2). Collectively, these findings are at variance with results
obtained with GSS
P101L prions in transgenic mice, which lack
PrP8 and have a sPrP
Sc core fragment of 22–24 kDa [14]. Brain
homogenates from frontal cortex of GSS P102L subjects with and
without PrP27-30, digested with increasing concentrations of PK,
ranging from 5 to 50 mg/ml, and probed with 1E4, did not show
the ladder-like pattern observed in subjects with ‘‘variably
protease-sensitive prionopathy’’ (VPSP) and GSS A117V [26].
PrP IHC
In all investigated subjects, tissue deposition of PrP occurred as
different patterns, including synaptic-like, granular, diffuse, uni-
centricandmulticentricplaques(Fig.5A–F,Table3).Wealsonoted
a fine granular typeof PrPdepositionin the white matter,suggestive
Figure 2. Two-dimensional analysis of mutant and wild-type PrP27-30, C-terminal truncated fragments, and insoluble PrP
Sc species
in GSS P102L. (A) Immunoblot with 3F4 of PrP27-30 in case # 4 shows three sets of differently glycosylated charge isomers migrating between 30
and 20 kDa, in addition to three spots with a mass of 8 kDa and pIs from 8.4 to 9.6 (arrow). (B) After deglycosylation, the 3F4-reactive core fragment
resolves as five spots with net charges between 6.1 and 8.1. (C) ICSM 35 antibody decorates three major spots at 8.1, 7.7, 7.3, and a minor spot at 6.8.
(D) Proteinase K-resistant PrP
Sc probed with 3E2 shows the three sets of PrP27-30, in addition to acidic isoforms migrating at 20 and 14 kDa, which
after deglycosylation (E), resolved as a core fragment of six spots at 20 kDa, and C-terminal truncated species of 16–17- and 12–14-kDa. (F) In contrast,
the PrP27-30 core fragment associated to E200K mutation resolves as a major spot at pI of 6.8. Immunoblots of the detergent-insoluble fraction, show
the presence of naturally occurring PrP
Sc species with migration overlapping PrP27-30, the 8 kDa fragment (G), and C-terminal truncated fragments
(H). (I) Schematic diagram of PK-resistant mutant and wild-type PrP
Sc forms.
doi:10.1371/journal.pone.0032382.g002
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and ICSM 35 (Fig. 5D,5E,5F) antibodies, and, as far as in-
dividual plaques could be identified in consecutive paraffin- or
plastic-embedded sections (data not shown), we were unable to
observe ICSM 35-negative plaques. On the contrary, diffuse and
synaptic-like PrP deposits were exclusively labeled by 3F4, but not
Figure 3. Fractionation of mutant and wild-type PrP
Sc aggregates in GSS P102L. Brain homogenates from frontal cortexes of case # 5 (A,
B) and case # 8 (C, D) were sedimented in a 10 to 60% sucrose gradient. After sedimentation, half samples were digested with PK (E, F, G, H). (A) PrP
from case # 5 is distributed across all fractions albeit concentrated at the top (1–4) and at the bottom fractions (8–11); two bands of 11 and 8 kDa co-
localize with PrP
Sc in fraction 11. (B) Immunoblot with ICSM-35 of case # 5 shows lower amounts of PrP aggregates, with a distribution similar to that
observed with 3F4, in the absence of lower molecular species. (C) In case # 8, 3F4-reactive PrP was mainly distributed at the top and at bottom
fractions, whereas ICSM 35 showed very low amount of PrP in the bottom fraction (D). (E) Mutant PrP aggregates in case # 5 were resistant to PK
digestion; PK-resistant PrP
Sc species were more abundant in bottom fractions, containing also high amounts of the a smear spanning 8–12 kDa. (F)
ICSM 35 stained PK-resistant PrP
Sc from case # 5 were detected only in the bottom fractions. (G) In case # 8, PrP27-30 is absent, while an 8 kDa
fragment is detected at the fractions 9–11; on the contrary, no wild-type PrP species are seen (H).
doi:10.1371/journal.pone.0032382.g003
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against the N- and C-terminus disclosed a peripheral staining of
plaques (data not shown). PrP immunostaining in case # 3w a s
indistinguishable from that observed in GSS cases with PrP27-30
(Fig. 5G,5H). Conversely, in case # 8 an atypical pattern of PrP
deposition was seen within all cortical layers of the frontal cortex.
IHC with 3F4 showed synaptic-type positivity and ‘‘filamentous’’
PrP aggregates in a wavy pattern of deposition (Fig. 5I,5J). In this
case, packed PrP deposits were similar to the ‘‘curly’’ pattern
recently described by Colucci et al. in GSS H187R coupled with V
at codon 129 (H187R-129V haplotype) [27]; IHC with ICSM 35
revealed the association of fibrillary prion protein aggregates with
glial cell membranes. Additionally, punctuate PrP deposition was
observed in the white matter with both antibodies. Taken together,
in the two cases lacking PrP27-30 at immunoblot, deposition of
mutated and wt PrP was observed under diverging patterns, either
as granular and plaque deposits, or in a wavy motif. This further
confirmsthat sPrP
Scis involved into mechanisms ofaggregation and
tissue deposition.
PET-blot detection of abnormal PrP species
PET-blot with 3F4 (Fig. 6A,6B) and ICSM 35 (Fig. 6C,6D) was
performed on GSS P102L brain tissues samples from the frontal
cortex and cerebellum, in corresponding brain regions investigated
by IHC. PrP deposition under granular and plaque aggregates was
identified with both antibodies in all investigated frontal and
cerebellar sections, including cases with and without PrP27-30; no
PrP deposition was detectable in the tissues of the non-prion
control group. The immunolabeling obtained with the PET blot
method showed a pattern similar to that observed with IHC, with
the exception of the synaptic pattern, which could not be clearly
assessed owing to the resolution limitations of sections examined
with this technique. To date, PET-blot has been performed only in
one GSS case [28], but not with antibodies recognizing PrP
wt, and,
more importantly, not in cases lacking PK-resistant PrP
Sc.
Therefore, the present results, have important implication for
the diagnostic role of this methodic in prion diseases.
Discussion
The results reported here show that the heterogeneity of PrP
Sc
species associated with GSS P102L mutation is wider than
previously reported and is characterized by different degree of
involvement of PrP
M and PrP
Wt (Fig. 7). Our findings also provide
important clues as to the relative contribution of allelic PrP
molecules to neuropathological changes and tissue accumulation
of PrP and, in turn, on the sensitivity of IHC and PET blot in
detecting pathological forms of prion protein.
We show that the composition of rPrP
Sc forms in GSS P102L is
more heterogeneous than previously recognized, since, in addition
to PrP27-30 and PrP8, discrete amounts of CTFs with an
intermediate migration at 16–17 kDa and 12–14 kDa were found.
Using conventional and sensitive protein separation techniques,
we confirm the different glycotype between rPrP
M and rPrP
Wt
PrP27-30 [24], and, moreover, we show that rPrP
M and rPrP
Wt
have distinct conformations. These conclusions are highlighted by
the heterogeneous composition of PrP27-30 core fragment,
including distinct 3F4- and ICSM 35-positive PrP
Sc charge
isomers, whose characterization was not possible under conven-
tional Western blot [24]. This hybrid pattern, reflecting the
distinct contribution of rPrP
M and rPrP
Wt, was independent from
polymorphic codon 129 since it was observed in MM and MV
subjects. In addition, the 3F4-positive core fragment was at
variance with fCJD E200K, sharing a diglycosylated dominant
pattern of PrP27-30 with GSS P102L, therefore ruling out any
influence of the glycosylation status. The combined contribution of
PrP
M and PrP
Wt to PrP27-30 species is likely to account for the
molecular complexity of pathological prion protein in GSS P102L
cases and for its influence into the phenotypic variability
throughout propagation of distinct and multiple molecules.
The detection of CTF16-17 in GSS P102L subjects with PrP27-
30 speaks in favor of an aberrant endogenous proteolytic pathway
of PrP
Sc, as suggested by their detection in the native insoluble
fraction, and provides molecular support to similarities with sCJD
with type 1 PrP
Sc and MM2 subtype [6]. On the contrary, the
significance of CTF12-14 is less clear, since these species have
been detected in all molecular types of sCJD; their presence in
GSS P102L cases is intriguing, given the strict contiguity of the N-
terminus of CTF12-14 at amino acid 154–167 with the C terminus
of PrP8 at 146–153. Zou et al. previously observed that, in sCJD,
CTF12-14 likely originate from a subpopulation of PrP
Sc distinct
Figure 4. Protease-sensitive PrP
Sc conformers in GSS P102L
brain tissues. (A) Immunoblot with 3F4 of brain homogenate from
case # 2 digested with PK before (lane 1) and after PNGase treatment
(lane 2); lanes 3 to 6 show products of ‘cold PK’ (cPK)-treated
homogenates, before (lanes 3 and 5) and after (lanes 4 and 6) PNGase
treatment; in lanes 5 and 6 samples were NaPTA-precipitated; (B) cPK-
treated (lanes 7–10) and NaPTA precipitated products (lanes 9 and 10)
were revealed with ICSM 35, prior (lanes 7 and 9) or after
deglycosylation. (C) Immunoblot with 3F4 of brain extracts from case
# 8, after conventional PK treatment, shows a barely detectable 8 kDa
band (lanes 1,2, arrow); in contrast, after cPK digestion (lanes 3 to 6) and
NaPTA precipitation (lanes 5 and 6) consistent amounts of PrP27-30 and
of the 8 kDa fragment are seen (lane 3–6) in PNGase untreated (lanes 3
and 5) or treated (lanes 4 and 6) preparations. (D) In case # 8,
immunoblot with ICSM 35 did not reveal PrP
Sc after cPK treatment
(lanes 7 and 8), wheras NaPTA precipitation showed a smear migrating
in the upper part of the gel in a 50–70 kDa zone (lane 9, arrow), partially
decreased by PNFase treatment (lane 10).
doi:10.1371/journal.pone.0032382.g004
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due to their inability to detect PrP8 in preparations containing
CTF12-14, these authors considered unlikely the possibility that
two separate cleavages of the full-length PrP
Sc could result in the
generation of PrP-CTF12-14 and PrP8. The hypothesis that PrP8
and CTF12-14 are generated from different populations of PrP
Sc
is further strengthened by our findings showing the failure to
detect CTF12-14 in cases expressing only PrP8. Taken together,
our present results support the view that in GSS P102L PrP27-30,
PrP8, CTF16-17, and CTF12-14 species are generated by
multiple and distinct conformational pools of protease-resistant
PrP
Sc, likely originating from diverging subsets of protease-
resistant molecules. Although the allelic origin of N-terminally
truncated fragments in GSS could not be assessed, we argue that
CTFs may originate from both PrP
M and PrP
Wt.
Over the past few years, it has been shown that several prion
strains harbor protease-resistant and protease-sensitive PrP
Sc
molecules, and also that some human genetic and sporadic
conditions are characterized by the exclusive presence of protease-
sensitive PrP
Sc conformers. Further, a number of observations
have suggested that molecular species other that protease-resistant
PrP may be involved in the pathogenesis of GSS [12,13,14,15].
Hedge et al. first provided evidence that brain tissues from two
GSS subjects with the A117V mutation and from Tg mice
expressing various PRNP mutations had increased levels of
CTMPrP, a topological isoform of PrP
C, in the absence of
protease-resistant PrP
Sc [30]. In addition, these authors provided
experimental evidence about the central role of
CTMPrP in
inducing neurodegeneration. The detection of neurotoxic PrP
isomers was possible thanks to the ‘‘cold PK’’ digestion, an assay
conceived to detect subtle conformational differences in proteins,
taking advantage of their differential sensitivity to a weakly active
protease. This alternative method was more recently employed to
detect pathological conformers of the prion protein, other than
PK-resistant PrP
Sc, in transgenic mice expressing the equivalent
human P102L GSS mutation at codon 101 (P101L), which
develop spontaneous prion disease, as well as in Tg mice
inoculated with brain homogenates from GSS P102L patients
expressing valine or methionine at codon 129, and in the brain of
a P102L M129 GSS case [14]. Collectively, the foregoing
experiments have provided evidence that in the P102L mutation
alternative misfolding pathways take place, inducing the formation
of abnormal conformers other than PK-resistant PrP
Sc, which can
revealed by the ‘‘cold PK’’ assay. However, one biochemical
feature of these experimental studies is the striking absence of
PrP8, either among protease-resistant PrP species or sPrP forms,
and the lack of information regarding the allelic derivation of
distinct abnormal PrP species.
In this study, the issue of sPrP
Sc and rPrP
Sc in P102L was
investigated, after the evidence of different pools of PrP
Sc with
variable distribution in sedimentation profile, and diverging
resistance to conventional PK treatment. We introduced PK
digestion in ‘‘cold condition’’ to preferentially detect sPrP
Sc species,
in parallel to the canonical PK digestion at 37uC which retrieves
rPrP
Sc molecules. Obtained results confirm earlier experimental
findings inTg mice on the presence of significant levels of ‘‘cold PK-
resistant’’ PrP
Sc in all cases. Under the foregoing experimental
conditions we confirm that sPrP
Sc from the mutated and wt alleles
generate fragments withmolecular weight similar to those of rPrP
Sc,
an issue not investigated by Wadsworth and collaborators [24].
Noteworthy, cold PK sensitive PrP27-30 e PrP8 were found also in
cases lacking rPrP
Sc, and they were highly retrieved by PTA
precipitation. The biochemical properties of P102L sPrP
Sc species
weredistinct from molecular PrPformsencountered inGSSA117V
and in VPSPr [26]. These findings indicate that different human
prion diseases are characterized by the generation of multiple
conformational quasispecies of sPrP
Sc [31].
Despite the wide use of PrP IHC in the diagnosis of prion
diseases, it is still unclear which molecular forms of PrP
Sc are
detected by IHC after formic acid treatment and hydrolytic
Table 2. Allelic derivation and semiquantitative analysis of protease-resistant and protease-sensitive pathological prion protein
species in P102L GSS cases.
Case (code)
Conventional PK treatment
(100 mg/ml 376C)
Cold PK treatment
(250 mg/ml 46C)
3F4 ICSM-35 3F4 ICSM-35 (PTA)
PrP27-30 8 kDa PrP27-30 8 kDa PrP27-30 8 kDa PrP27-30 8 kDa
1
(91-466)
+++ +++ +/22 +++ +++ +++ 2
2
(92-331)
++ ++ +/22 ++ ++ +++ 2
3
(96-422)
2 ++ 22 ++ + 22
4
(98-196)
++ + +/22 ++ + +++ 2
5
(98-197)
+++ + +/22 +++ + +++ 2
6
(2004-59)
+++ + +/22 +++ + +++ 2
7
(2005-51)
+++ ++ +/22 ++ ++ 2(*) 2
8
(2005-52)
2 + 22 ++ ++ +/22
(*)in the upper part of the gel a smear is observed (see figure 5D). Scores: 2 (negative); +/2 (faint); + (weak); ++ (moderate); +++ (intense).
doi:10.1371/journal.pone.0032382.t002
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limitation in using IHC as a diagnostic tool in prion diseases. It has
been argued that autoclaving of tissue sections, treated with formic
acid, might destroy only PrP
C and sPrP
Sc (also lost after limited
proteolysis with PK), but not rPrP
Sc that is only denatured.
However, this explanation is in contrast with our present IHC and
PET blot results, showing PrP deposition in cases lacking rPrP
Sc
species. Therefore, the diagnostic sensitivity of IHC and PET blot
as compared with immunoassay, needs to be reassessed in prion
diseases, also taking account of the fixation protocol. According to
our present results, PrP
M contributes to synaptic-type staining,
whereas both PrP
wt and PrP
M concur to granular, axonal, and
amyloid PrP deposition. Further, PET blot analysis with both 3F4
and ICSM35 showed a comparable staining of PrP plaques, in
sections that were stained following PK digestion. To explain the
present results we suggest that fixation with formalin may induce
protein-protein covalent cross links, owing to reactivity of
formaldehyde with side chain moieties of lysyl, arginyl, tyrosyl,
aspartyl, histidyl, and seryl residues. These changes might induce
sPrP
Sc to acquire resistance to chemical and physical treatments,
including protease digestion. This line of thinking is readily evident
when one considers that cases bearing only the internal PrP8
fragment, in the absence of 3F4- and ICSM 35-positive PrP27-30,
showed marked deposition of PrP
Wt. The present findings lend
support to results obtained in GSS H187R-129V, showing intense
PrP deposition under ‘‘curly’’ plaques in spite of minimal amount
of rPrP
Sc [27], and expand the range of GSS mutations associated
with curly-like sPrP
Sc deposition.
The present findings widen the spectrum of propagating PrP
Sc
isoforms in P102L GSS, thus providing further molecular support
to explain the ample phenotypic heterogeneity observed in this
inherited condition.
Materials and Methods
Ethics statement
All studies and procedures were done under protocols approved
by the Institutional Review Board at Indiana University. The
brains of all subjects included in the study were obtained after the
families had expressed a strong wish that we study them
neuropathologically and carry out research. The brains were
harvested with full cooperation of the pathologists involved and
following the family’s written informed consent.
Patients and tissue samples
The eight subjects analyzed in the present study were from
four unrelated kindred (Table 1). Pedigrees, clinical features,
neuropathological and molecular data of 5 cases (91-466, 92-
331, 96-422, 98-196, 98-197) have been previously reported.
Frozen and formalin-fixed brain tissues from all patients
were used for the present study. Control brains were obtained
from subjects not affected by prion diseases. The use of stored
Figure 5. Mutant and wild-type PrP immunostaining in GSS P102 L. IHC with the 3F4 antibody shows PrP deposition under diffuse, synaptic-
like, and plaques aggregates in the frontal cortex (A, B) and in the cerebellar cortex (C) of case # 3; IHC with ICSM 35 in adjacent sections of the same
subject immunodecorates PrP plaques in both frontal cortex (D, E) and cerebellum (F), but not diffuse or synaptic-like PrP deposits. (G) Frontal cortex
from case # 3 showing 3F4-positive plaques, as well as of granular/synaptic-like PrP deposits; the punctuate and granular patterns are less evident
with the ICSM 35 antibody (H), whereas a similar stain is obtained for plaques. (I) 3F4 immunostaining of the frontal cortex from case # 8 showing a
widespread PrP deposition involving all cortical layers; the PrP pattern of deposition is ‘‘curly-like’’; (J) immunostaining with ICSM 35 in an adjacent
section shows a curly PrP deposition in the outer layer of cortex as well as a pericellular staining.
doi:10.1371/journal.pone.0032382.g005
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committee.
Genetic analysis
Analysis of PRNP was performed by using genomic DNA
extracted from frozen brain tissue. Amplification of the PRNP
coding region was obtained by polymerase chain reaction; the
codon 129 genotype and the codon 102 mutation were determined
by restriction enzyme analysis, as previously described [9]. PRNP
sequence analyses showed the presence of allelic P102L point
mutation coupled with methionine at codon 129 in all cases. Five
patients were methionine homozygous at PRNP codon 129,
whereas three patients were heterozygous.
Immunoblot analysis
Brain samples were homogenized in 9 volumes of lysis buffer
(100 mM sodium chloride, 10 mM EDTA, 0.5% Nonidet P-40,
0.5% sodium deoxycholate, 10 mM Tris, pH 7.4) and clarified by
centrifugation at 1,0006g for 10 min. The supernatant (S1) was
stored at 280uC until use and the pellet discarded. S1was
centrifuged at 100,000g for 90 min at 4uC. The supernatant (S2)
was saved and the pellet was resuspended in lysis buffer and
centrifuged as above. The final pellet (P3) was designated as
detergent-insoluble, whereas the detergent-soluble fraction was
referred to the final combination of S2 and S3. Protease resistance
was assayed by incubating sample aliquots containing 40 mgo f
total protein with 100 mg of proteinase K (Boehringer Mannheim,
Germany) per milliliter at 37uC for 60 minutes. For ‘‘cold PK’’
digestion, clarified 10% brain homogenates containing 1% NP-40
were incubated with 250 mg of PK/ml for 1 h on ice and
thereafter treated according to the protocol of Tremblay et al.
Table 3. Immunohistochemical analysis of allelic prion protein species in P102L GSS.
Case (code) Frontal Cortex Cerebellum
3F4 ICSM 35 3F4 ICSM 35
1
(91-466)
++++
Multicentric cortical and subcortical
plaques; granular cortical staining.
Axonal staining (Fig. 3A, 3C, 3G)
++
As with 3F4, but less intense
granular and axonal deposition
(Fig. 3B, 3D, 3H)
++++
Amyloid plaques; granular depo-
sition in the granular layer (Fig. 3E)
+++
Granular and
axonal staining
(Fig. 3F)
2
(92-331)
+++
Diffuse staining and multicentric
plaques
++
Weaker reactivity of plaque core, as
compared to 3F4
+++
Diffuse staining and multicentric
amyloid plaques
++
Weaker staining of
plaque core
3
(96-422)
++++
Granular deposition, multicentric
amyloid plaques (Fig. 3 I)
++
As with 3F4, but less intense granular
and axonal deposition (Fig. 3J)
++++
Amyloid plaques in molecular and
granular layers; axonal deposition
++
Weaker staining of
amyloid plaques
4
(98-196)
N.A. N.A. N.A. N.A.
5
(98-197)
N.A. N.A. N.A. N.A.
6
(2004-59)
+++
Diffuse plaques, granular deposition
on the whole cortex. Plaques and
axonal staining in the white matter
++
As with 3F4, except for reduced
granular and axonal staining
++++
Numerous multicentric amyloid
plaques involving the whole cere-
bellum. Axonal staining
++
Granular and
axonal deposition
7
(2005-51)
+++
Granular staining and amyloid plaques
++
As with 3F4, except for the
absence of granular staining
N.A. N.A.
8
(2005-52)
++++
‘‘Curly-like’’ pattern in the cerebral
cortex. Intense axonal staining in the
white matter (Fig. 3K and 3M)
++
Diffuse staining (Fig. 3L and 3N)
+
Synaptic-type deposition in the
molecular layer
2
N.A. Not available. Scores: 2 (negative); + (light); ++ (mild); +++ (moderate); ++++ (intense).
doi:10.1371/journal.pone.0032382.t003
Figure 6. Paraffin-embedded tissue-blot analysis of mutant
and wild-type PrP. Detection of proteinase K-resistant forms of
mutant (A, B) and wild-type (C, D) prion protein in the cerebellum of
case # 1, as decorated by 3F4 and ICSM 35 antibodies; g denotes the
granular layer, and m denotes the molecular layer.
doi:10.1371/journal.pone.0032382.g006
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inhibitor (5 mM phenylmethylsulfonyl fluoride). Phosphotungstate
(PTA) precipitation, after cold PK digestion, was done as
previously described [32]. For N-deglycosylation, samples were
treated with N-glycosidase F (PNGase F) according to the
manifacturer’s instructions (Boehringer, Mannheim) for 8 hours
at 37uC. Proteins were dissolved in sample buffer (3% SDS, 3% b-
mercaptoethanol, 2 mM EDTA, 10% glycerol, 62.5 mM Tris,
pH 6.8) and boiled for 5 minutes. An equivalent of 0.4 mg of wet
tissue was loaded on 12% SDS-PAGE gels and proteins
transferred onto PVDF membrane (Immobilon P, Millipore) for
2 hours at 60 V. Membranes were blocked with 1% non-fat dry
milk in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween-20,
pH 7.5) for 1 hour at 37uC and incubated overnight at 4uC with
the following anti-human PrP monoclonal antibodies: 3F4
recognizing human PrP residues 106–110 (1:10.000), ICSM 35
whose epitope spans residues 93–105 and specifically detects wild-
type but not P102L human PrP, 6H4 directed to residues 144–152
(Prionics, 1:5000), 3E2 directed to human PrP residues 214 to 231
(1:500) (kindly donated by Dr. Capucci), and mouse monoclonal
antibody 1E4 against human PrP residues 97–108 (Cell Sciences,
Inc., Canton, MA). Blots were developed with an enhanced
chemiluminescence system (ECL, Amersham) and PrP visualized
on autoradiography films (Hyperfilm, Amersham). Films were
scanned by using a densitometer (GS-200, Biorad).
Two-dimensional gel electrophoresis
For isoelectric focusing (IEF), using immobilized pH gradients
(IPG) in the first dimension, pre-cast gels with a linear pH range of
3–10 were used (Biorad). Before IEF, the dry gels were reswollen
for 14–15 hours in 125 ml of buffer (6 M urea, 2 M thiourea, 5%
b-mercaptoethanol, 2% Nonidet P-40, and 2% ampholyte)
containing an equivalent of 2 mg of wet tissue. IEF was carried
out at 20uC for 4 hours with raising voltage (500–8000 V), in a
cooled horizontal electrophoresis unit (IPGphor, Pharmacia). For
the second dimension, the IPG strips were equilibrated for
20 minutes in 50 mmol/L Tris-HCl, 6 M Urea, 10% glycerol,
2% SDS and a trace of bromophenol blue and loaded on a 16%
SDS-PAGE. Immunoblotting was performed as described above
and PrP was revealed with 3F4 (1:10.000, Dako), 3E2 (1:500) and
ICSM 35 (1:1000, D-Gen).
Sedimentation velocity in sucrose gradient
The S1 fractions prepared by centrifugation of 20% brain
homogenates at 8000 g for 5 min at 4uC were incubated with an
equal volume of 2% Sarkosyl for 30 min on ice. The samples were
loaded atop a 10–60% step sucrose gradient and centrifuged at
200,000 g for 1 h at 4uC, as described by Tzaban et al. [33].
Eleven fractions were collected from the top of the tube for
Western blot analysis of PrP.
PrP immunohistochemistry
Paraffin sections that were 8 mm thick were deparaffinized,
rehydrated in descending graded alcohols, treated with 98 percent
formic acid for 20 minutes at room temperature, and autoclaved
at 121uC for 10 minutes in 1.5 mM hydrochloric acid. Sections
were rinsed and then incubated overnight at 4uC with monoclonal
antibody 3F4 (1:500 dilution) and ICSM 35 (1:250). Subsequent
antibody detection involved incubation with a biotinylated goat
anti-mouse secondary antibody for one hour (1:500 dilution,
Vector Laboratories) at room temperature, followed by incubation
with the avidin–biotin–peroxidase complex (Vectastain ABC-Elite
kit, Vector Laboratories) according to the manufacturer’s
instructions. The samples were then stained with 0.06 percent
3,39-diaminobenzidine as the chromogen and 0.006 percent
hydrogen peroxide in 50 mM Tris buffer, pH 7.6.
Paraffin-embedded tissue blot (PET-blot)
Paraffin sections, 7 mm thick, were collected on prewetted
0.45 mm-pore nitrocellulose membrane and dried for 30 minutes.
The sections were thereafter deparaffinized, rehydrated, and
treated with 250 mg/ml of proteinase K for 4 h at 37uC. Sections
were incubated with monoclonal antibodies 3F4 and ICSM 35.
After washing in TBST, incubation with an alkaline phosphatase-
coupled rabbit anti-mouse antibody (Dako) was done. The
membranes were then adjusted to alkaline pH by exposure to
NTM (100 mmol/L Tris-HCl, pH 9.5; 100 mmol/L NaCl;
Figure 7. Diagram of PK-resistant and PK-sensitive PrP
Sc molecules detected in GSS with the P102L mutation. PrP
Sc species originating
from the mutant allele are depicted in orange, whereas wild-type PrP
Sc molecules are depicted in green. PrP8 is an internal PK-resistant fragment
spanning residues 74/90 to 146/153. PrP27-30 is the main C-terminal PK-resistant PrP fragment generated by PK cleavage between PrP
Sc residues 74
and 103. PrP-CTF 16/17 and PrP-CTF 12/13 are smaller PK-resistant fragments whose allelic origin remains undetermined (depicted in blue).
doi:10.1371/journal.pone.0032382.g007
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was provided by formazan reaction using NBT/BCIP. Blots were
evaluated with an Olympus microscope.
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